In patients with very high risk, high grade T1 with CIS NMIBC, the possible value of adding immune checkpoint blockade to BCG has not been defined.

Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG ...

May 14 (Reuters) - AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to ...

An existing oral drug already used to treat lung cancer could help improve survival rates for bladder cancer patients, a new clinical trial by UK scientists has found. There are approximately 10,300 ...

Enfortumab vedotin plus pembrolizumab significantly improves EFS and OS in cisplatin-ineligible MIBC patients, offering a new treatment option. The EV-303 trial is the first to show systemic treatment ...

SAN FRANCISCO -- Radiation therapy (RT) after surgery for high-risk muscle-invasive bladder cancer significantly reduced the rate of local recurrence and improved survival, according to a randomized ...

Real-world effectiveness and treatment patterns in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in Japan: Long term follow-up from the ...

ImmunityBio Inc. on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory to ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder cancer compared with those who can see colors. The researchers hypothesized ...

SALT LAKE CITY — The five-year survival rate for all cancers combined has reached a historic 70%, according to the latest American Cancer Society Cancer Statistics 2026 report, based on all people ...